FDA Inspection 1027562 — Halo Pharmaceutical, Inc. D/B/A Cambrex Whippany
The FDA completed an inspection of Halo Pharmaceutical, Inc. D/B/A Cambrex Whippany on Aug 24, 2017 in Whippany, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Aug 24, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Whippany, NJ (United States)